Constellation Brings In Series B Totaling $22 Million, Including GSK Investment
This article was originally published in The Pink Sheet Daily
Executive Summary
Involvement by GSK's venture arm SR One enables Constellation to keep pace with epigenetics competitor Epizyme, which is backed by Amgen and Astellas.
You may also be interested in...
Genentech, Constellation Enter Largest Epigenetics Tie-Up Yet
For $95 million guaranteed, Genentech gains rights to broad research in the emerging field over a three-year period, as well as an option to acquire the start-up outright.
GSK Teams Up With EpiZyme To Develop Epigenetic Drugs
The Cambridge, Mass., biotech, a leader in epigenetics, garners its first big pharma partner.
GSK Teams Up With EpiZyme To Develop Epigenetic Drugs
The Cambridge, Mass., biotech, a leader in epigenetics, garners its first big pharma partner.